Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP Draft Medicare Formulary Sets 146 Drug Categories And Classes

Executive Summary

U.S. Pharmacopeia's draft model for Medicare prescription drug formularies establishes 146 unique therapeutic categories and pharmacologic classes, falling in between the numbers of drug groups sought by drug manufacturers and PBMs

You may also be interested in...



USP “Key Drug Types” Could Serve As CMS Standard For Medicare Rx Plans

The U.S. Pharmacopeia hopes its list of "formulary key drug types" will become the CMS standard for reviewing the appropriateness of Medicare Rx plans' drug lists

USP Final Formulary Guide Adds PPI Class, But Has Few Other Changes

Proton pump inhibitors may be the only commercially significant group of drugs to gain "pharmacologic class" status in the revisions to U.S. Pharmacopeia's model guidelines for Medicare drug plans

USP “Key Drug Types” Could Serve As CMS Standard For Medicare Rx Plans

The U.S. Pharmacopeia hopes its list of "formulary key drug types" will become the CMS standard for reviewing the appropriateness of Medicare Rx plans' drug lists

Related Content

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel